Back to discover

Protein / target

Epithelial cell adhesion molecule

Encoded byEPCAMP16422Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
3
Approved medicines
Open Targets target-level
View by indication →
15
Clinical trials
Small-molecule tractable
Druggability
Structure with Ligand

Protein at a glance

Biological role

Cadherin binding involved in cell-cell adhesion

Strongest disease association

Stomach Neoplasms

Via encoding gene EPCAM · Genetic evidence · score 0.86

Therapeutic position

Established drug target

Antibodies

Research activity

Emerging research

1 papers · latest 2020

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection.

View complete UniProt function annotation

May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E

Subcellular location

Lateral cell membraneCell junction, tight junction
Domains and Gene Ontology detail (17)

Domains & features

Thyroglobulin type-1

Gene Ontology

  • Capical plasma membrane
  • Cbasolateral plasma membrane
  • Cbicellular tight junction
  • Ccell surface
  • Cextracellular exosome
  • Clateral plasma membrane
  • Cplasma membrane
  • Fcadherin binding involved in cell-cell adhesion
  • Fprotein-containing complex binding
  • Pnegative regulation of cell-cell adhesion mediated by cadherin
  • Ppositive regulation of cell population proliferation
  • Ppositive regulation of stem cell proliferation

314 aa · 35 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell proliferation & survivalGOCell adhesionUniProt · GOTranscriptional regulationGO
View supporting evidence

Cell proliferation & survival

  • ·positive regulation of cell population proliferation

Cell adhesion

  • ·Cell junction, tight junction
  • ·bicellular tight junction
  • ·cadherin binding involved in cell-cell adhesion
  • ·negative regulation of cell-cell adhesion mediated by cadherin

Transcriptional regulation

  • ·positive regulation of transcription by RNA polymerase II
  • ·signal transduction involved in regulation of gene expression

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Approved medicines with mapped indications

1 medicine · 1 area

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Neoplasms1 medicine

3 medicines meet Open Targets' target-level approved-medicine definition; the 1 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

catumaxomab
ApprovedCross-linking agent

Epithelial cell adhesion molecule cross-linking agent

Indicated for Neoplasms

Direct interaction with this protein · 1 of 4 recorded protein targets

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene EPCAM

Gene-level evidence surfaced through the gene EPCAMthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Stomach Neoplasms
0.92Well supported

Genetic evidence dominant · Open Targets 0.60

Colon carcinoma
0.70Moderately supported

Genetic evidence dominant · Open Targets 0.42

Colorectal Neoplasms, Hereditary Nonpolyposis
0.69Moderately supported

Genetic evidence dominant · Open Targets 0.51

Inherited cancer-predisposing syndrome
0.69Moderately supported

Genetic evidence dominant · Open Targets 0.42

Neoplasms
0.68Moderately supported

Clinical evidence dominant · Open Targets 0.53

View evidence synthesis (5)
Stomach NeoplasmsWell supported
0.92
agreement 0.811.00
Genetic65%Clinical24%Literature10%

Open Targets aggregate 0.60 · 3 independent evidence families

Colon carcinomaModerately supported
0.70
agreement 0.560.84
Genetic94%Literature6%

Open Targets aggregate 0.42 · 2 independent evidence families

Colorectal Neoplasms, Hereditary NonpolyposisModerately supported
0.69
agreement 0.570.81
Genetic70%Animal model20%Literature11%Genetic literaturedup

Open Targets aggregate 0.51 · 3 independent evidence families · 1 not counted as duplicate

Inherited cancer-predisposing syndromeModerately supported
0.69
agreement 0.550.83
Genetic98%Literature2%

Open Targets aggregate 0.42 · 2 independent evidence families

NeoplasmsModerately supported
0.68
agreement 0.520.83
Clinical81%Literature19%

Open Targets aggregate 0.53 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Stomach Neoplasms0.60
Neoplasms0.53
Colorectal Neoplasms, Hereditary Nonpolyposis0.51
Colon carcinoma0.42
Colorectal Neoplasms0.42
Inherited cancer-predisposing syndrome0.42

Drug development

10 compounds recorded · 3 approved · 7 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph (1 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (10)
IGN-101Phase 2
TUCOTUZUMAB CELMOLEUKINPhase 2
ADECATUMUMABPhase 2
CATUMAXOMABApproval
CITATUZUMAB BOGATOXPhase 1
EDRECOLOMABApproval
SOLITOMABPhase 1
OPORTUZUMAB MONATOXApproval
ING-1Phase 1
MOC31-PEPhase 1

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand) — no clinical-stage drug of this modality recorded.

AntibodiesStrong

Approved Drug and UniProt loc high conf support this modality.

Protein degradersEmerging

Feasibility evidence (database ubiquitination) — no clinical-stage drug of this modality recorded.

Other modalitiesStrong

Advanced Clinical support this modality.

View underlying tractability evidence (8)
SM · Structure with LigandAB · Approved DrugAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMAB · Human Protein Atlas locPR · Database UbiquitinationOC · Advanced Clinical

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

15

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (11)

ClinicalTrials.gov via the drug-target graph.

What's happening now

1

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Regulatory approval2025-02-10

    Approval: Korjuny (EMA)

    ema · regulatory · ema · via catumaxomab

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.

Research activity

1 papers · to 2020

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.